By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Alcaftadine is used to stop allergic conjunctivitis from causing eye irritation. It is an antagonist of the H1 histamine receptor. It inhibits the activity of three histamine receptors (1, 2, and 4). Alcaftadine’s primary use is to stop allergic conjunctivitis from occurring.
It has been demonstrated to greatly lessen the impact of allergens by inhibiting these three receptors. After exposure to an allergen, itching, eosinophil recruitment, and redness appear to be less frequent as a result of this action on histamine receptors.
Compared to olopatadine 0.1%, alcaftadine’s action appeared to dramatically reduce the number of eosinophil cells.
Alcaftadine 0.25% appeared to perform better than placebo at reducing E-cadherin expression when alcaftadine was tested in animal models. As connections diminish due to a decrease in E-cadherin, allergic conjunctivitis will worsen.
Only Alcaftadine 0.25% was found to have a clinically meaningful reduction in conjunctival redness scores 7 and 15 minutes after delivery in comparison to placebo and olopatadine.
Treatment with all three of the alcaftadine groups (0.05, 0.1, and 0.25%) decreased secondary endpoints of (lid swelling, conjunctival redness, and ocular itching/tearing) when clinical groups were compared to placebo.
When comparing the efficacy of olopatadine to that of alcaftadine, it was shown that there was no increase in side effects with increasing doses of alcaftadine (0.05%, 0.1%, or 0.25%). The most often observed adverse reaction to alcaftadine administration was stinging or irritation at the administration site.
It is frequently administered as an eye drop, which prevents systemic effects and maintains its effects locally. Alcaftadine’s primary metabolite is a carboxylic acid metabolite with negligible systemic effects.
The primary active metabolite’s highest concentration is 0.06 ng/ml at a Tmax of 15 minutes. It has a limited systemic buildup due to its minimal absorption.
After ocular injection, the main metabolite of alcaftadine has a half-life of two hours. The remainder of alcaftadine is excreted unaltered, with the exception of the metabolite.
Alcaftadine appears to have limited systemic effects because it is given at a low dose and at a local site (the eye).
The Global ALCAFTADINE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
For the estimated 40% of Americans1 who suffer from ocular allergies, Allergan, an AbbVie company, announced that LASTACAFT (alcaftadine ophthalmic solution 0.25%) is now accessible without a prescription.
As shown, one drop of LASTACAFT relieves itchy, allergic eyes for up to 16 hours after just three minutes of application. 2 The original patented prescription-strength formulation of LASTACAFT is now accessible everywhere OTC eye drops are marketed as a result of the recent U.S. Food and Drug Administration approval of a complete prescription to over-the-counter (OTC) changeover.
